iBiopsy®: Median Technologies continues its strong positioning in early-stage diagnosis with a new iBiopsy® Clinical Development Plan on Lung Cancer Screening (LCS)
Median is building a cloud based end-to-end approach performing both localization and discrimination of malignant and benign lung lesions. The company plans to demonstrate the potential of deep learning models to increase the accuracy, consistency and adoption of lung cancer screening worldwide. First results for a proof of concept on a cohort of 1,800 patients are expected in H2, 2021.
Read more